-+ 0.00%
-+ 0.00%
-+ 0.00%

Exelixis shares fell 3% after the US Food and Drug Administration extended the review period for the company's anti-cancer drugs.

智通財經·09/11/2026 13:41:19
語音播報
Exelixis shares fell 3% after the US Food and Drug Administration extended the review period for the company's anti-cancer drugs.